Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Surrinder Dang (NPI 1699755116)

Field	Value
Entity Type	Individual
Organization	Surrinder Dang
Address	1 Hospital Dr Sw Ste 400
City	Huntsville
State	AL
ZIP	35801
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 19, 2006

Payer Source	Total Paid
Medicare	$1.9M
Medicaid	$0

Key Findings

This provider reports $1.9M in lifetime Medicare revenue and has no Medicaid billing on file, making their public claims history effectively single‑payer (Medicare) in scale. The absence of Medicaid billing suggests limited participation in that program or no fee-for-service Medicaid activity captured in the data set.

Revenue is highly concentrated in a small number of drug codes: the precomputed top‑3 Medicare codes account for 70.6% of total Medicare revenue, driven by J9271 ($851.4K, 47.5%), J0897 ($252.7K, 14.1%), and J1568 ($161.8K, 9.0%). This concentration indicates that a few high-cost infusions dominate reimbursement for this clinician.

The code mix—led by J9271 (pembrolizumab), J0897 (denosumab), and J1568 (intravenous immune globulin)—is consistent with an oncology/hematology infusion practice that delivers oncology immunotherapy, bone-modifying agents, and immune globulin therapies. Ancillary chemotherapy administration codes such as 96413 ($45.3K, 2.5%) and infusion-related codes like 96365 and G0498 further support an operational model centered on in‑office infusion and chemotherapy delivery.

Competitive standing for the top revenue drugs is mixed: J9271 ranks #406 of 1841 providers nationally (77th percentile; typical, unremarkable volume for this code), J0897 ranks #607 of 10057 (94th percentile; typical, unremarkable volume for this code), and J1568 ranks #107 of 381 (72th percentile; typical, unremarkable volume for this code). In plain terms, the provider is a relatively strong national participant on denosumab (J0897) and a solid but not dominant participant on pembrolizumab (J9271) and IVIG (J1568).

Visit-level billing shows an anomalously high volume of established outpatient E/M visits: 99214 accounts for $98.3K (5.5%) and is flagged as an "extreme outlier, far above typical national volume for this code" (rank #9166 of 479517, 98th percentile). This suggests either a high patient throughput for established visits in clinic or a sustained focus on frequent longitudinal outpatient management.

Several routine lab and phlebotomy codes appear at very high national percentiles—80053 ($20.1K, 1.1%) ranks in the 98th percentile, 85025 ($16.8K, 0.9%) ranks in the 97th percentile, and 36415 ($13.2K, 0.7%) ranks in the 99th percentile—all labeled "typical, unremarkable volume for this code" despite their high percentiles. These patterns are consistent with on‑site specimen collection and frequent lab monitoring to support oncology care and treatment monitoring.

Certain infusion-related administration codes show above-typical national activity: 96375 ($10.2K, 0.6%) is described as "notably above typical national volume for this code" (rank #190 of 5191, 96th percentile), while 96413 ($45.3K, 2.5%) is at the 90th percentile and described as "typical, unremarkable volume for this code." Together these suggest active use of IV push and infusion sequencing in the practice's treatment workflows.

The provider's NPI was enumerated on 2006-01-19 (~20 years ago), indicating long tenure in the Medicare program. This duration supports the likelihood of an established referral base and an operational practice infrastructure that aligns with the sustained infusion and outpatient visit volumes reported above.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

73 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	19,800	$40	$851.4K
J0897	Injection, denosumab, 1 mg	14,040	$20	$252.7K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	4,760	$30	$161.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,090	$90	$98.3K
Q5127	Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg	350	$270	$95K
J1437	Injection, ferric derisomaltose, 10 mg	3,500	$20	$56K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	490	$90	$45.3K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	100	$350	$33.3K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	240	$130	$32.5K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	13,260	$1	$26.5K

Showing 1–10 of 73

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 73 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Surrinder Dang — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

73 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	18	30	19,900	$40	$827.2K
J1568	21	30	5,180	$30	$316.2K
Q5127	13	20	590	$270	$165.7K
J0897	13	200	3,120	$20	$97.7K
J1437	18	40	3,000	$20	$59.1K
J1454	11	20	90	$340	$33.7K
J0881	6	30	7,720	$1	$24.1K
96413	21	150	150	$90	$20.2K
99214	132	7,330	120	$80	$16.8K
82306	127	340	60	$30	$16K

Showing 1–10 of 73

Related Providers

Other providers that share a Tax Identification Number (TIN) with Surrinder Dang, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
John Waples	AL	Medical Oncology Physician	$9.6M	$0
Marshall Schreeder	AL	Medical Oncology Physician	$3.5M	$0
Heather Brody	AL	Hematology & Oncology Physician	$3.1M	$0
Jorge Diaz	AL	Hematology & Oncology Physician	$2.6M	$0
Naveen Lobo	AL	Medical Oncology Physician	$2.4M	$0
Ali Hachem	AL	Hematology & Oncology Physician	$2.3M	$0
Daniel Schreeder	AL	Hematology & Oncology Physician	$2.3M	$0
Robert Conry	AL	Hematology & Oncology Physician	$2.1M	$0
Lakshmikanth Katragadda	AL	Hematology & Oncology Physician	$2.1M	$0
Oncology Specialties, P.C.	AL	Hematology & Oncology Physician	$0	$2M

Nearby Providers

Other providers in the same ZIP code as Surrinder Dang, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tennessee Valley Neonatology, Inc	AL	Neonatal-Perinatal Medicine Physician	$0	$22.2M
The Health Care Authority Of The City Of Huntsville	AL	General Acute Care Hospital	$0	$17.8M
Happi Health	AL	Federally Qualified Health Center (FQHC)	$0	$17.6M
Emergency Physicians Group	AL	Emergency Medicine Physician	$0	$13.5M
Healthgroup Of Alabama	AL	Contractor	$0	$13.4M
The Valley Foundation	AL	Multi-Specialty Clinic/Center	$0	$11.3M
David White	AL	Neurology Physician	$7M	$0
The Children's Hospital Of Alabama	AL	Pediatric Pulmonology Physician	$0	$5.6M
Huntsville Pediatric Associates, LLC	AL	Pediatrics Physician	$0	$4.8M
Dental Associates Of Huntsville, LLC	AL	General Practice Dentistry	$0	$4.7M

Surrinder Dang — Billing Profile & Reimbursement Data

Sign up for Surrinder Dang — Billing Profile & Reimbursement Data policy alerts

Surrinder Dang — Billing Profile & Reimbursement Data

Sign up for Surrinder Dang — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References